[go: up one dir, main page]

BR0311774A - regimes de tratamento com bazedoxifeno - Google Patents

regimes de tratamento com bazedoxifeno

Info

Publication number
BR0311774A
BR0311774A BRPI0311774-0A BR0311774A BR0311774A BR 0311774 A BR0311774 A BR 0311774A BR 0311774 A BR0311774 A BR 0311774A BR 0311774 A BR0311774 A BR 0311774A
Authority
BR
Brazil
Prior art keywords
bazedoxifene
treatment regimens
bazedoxyphene
bazedoxefin
azepan
Prior art date
Application number
BRPI0311774-0A
Other languages
English (en)
Inventor
Simon N Jenkins
Barry S Komm
James C Ermer
Mark A Collins
Geraldine M Ferron
Pol Boudes
Wendy A Dulin
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BR0311774A publication Critical patent/BR0311774A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

REGIMES DE TRATAMENTO COM BAZEDOXIFENO A presente invenção refere-se a regimes de dosagem prolongados para o modulador seletivo do receptor de estrogênio bazedoxefina (1-¢4-(2-azepan-1-il-etóxi)-benzil!-2-(4-hidróxi-fenil)-3-metil-1H-indol-5- ol).
BRPI0311774-0A 2002-06-13 2003-06-13 regimes de tratamento com bazedoxifeno BR0311774A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38859602P 2002-06-13 2002-06-13
PCT/US2003/019011 WO2003105834A1 (en) 2002-06-13 2003-06-13 Bazedoxifene treatment regimens

Publications (1)

Publication Number Publication Date
BR0311774A true BR0311774A (pt) 2007-05-08

Family

ID=29736501

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0311774-0A BR0311774A (pt) 2002-06-13 2003-06-13 regimes de tratamento com bazedoxifeno

Country Status (20)

Country Link
US (1) US20040063692A1 (pt)
EP (1) EP1531807A4 (pt)
JP (1) JP2005531613A (pt)
KR (1) KR20050010886A (pt)
CN (1) CN1658868A (pt)
AU (1) AU2003248707A1 (pt)
BR (1) BR0311774A (pt)
CA (1) CA2489098A1 (pt)
CR (1) CR7585A (pt)
EC (1) ECSP045492A (pt)
IL (1) IL165210A0 (pt)
MX (1) MXPA04011634A (pt)
NI (1) NI200400065A (pt)
NO (1) NO20044954L (pt)
NZ (1) NZ537051A (pt)
RU (1) RU2355397C2 (pt)
SG (1) SG162615A1 (pt)
UA (1) UA85374C2 (pt)
WO (1) WO2003105834A1 (pt)
ZA (1) ZA200409991B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG149081A1 (en) * 2004-01-13 2009-01-29 Wyeth Corp Treatment of aromatase inhibitor therapy-related osteoporosis
CN1942177B (zh) * 2004-04-08 2011-05-25 惠氏公司 醋酸巴泽多昔芬固体分散剂型
KR20060134146A (ko) * 2004-04-08 2006-12-27 와이어쓰 선택적 에스트로겐 수용체 모듈레이터로서의 바제독시펜아스코르베이트
CA2601898A1 (en) * 2005-03-31 2006-10-05 Wyeth O-desmethylvenlafaxine and bazedoxifene combination product and uses thereof
BRPI0612586A2 (pt) * 2005-06-29 2010-11-23 Wyeth Corp formulações de estrogênios conjugados e bazedoxifeno
JP2009506053A (ja) * 2005-08-24 2009-02-12 ワイス 酢酸バゼドキシフェン製剤
CA2670544A1 (en) * 2006-11-29 2008-06-05 Wyeth Estrogen/ serm and estrogen/ progestin bi-layer tablets
ITMI20091109A1 (it) 2009-06-23 2010-12-24 Wyeth Corp Forma polimorfa d di bazedoxifene acetato e metodi per la sua preparazione
WO2013182169A1 (en) * 2012-06-07 2013-12-12 Zentiva, K. S. Process of preparation of an antioxidant-free polymorphically and chemically stable formulation of bazedoxifene acetate
KR101940569B1 (ko) * 2017-05-24 2019-01-21 아주대학교산학협력단 바제독시펜 또는 이의 약학적으로 허용가능한 염을 포함하는 약학 조성물
CN112076163B (zh) * 2019-06-14 2023-06-20 四川科伦药物研究院有限公司 一种醋酸巴多昔芬片的药物组合物及其制备方法
CN113244240A (zh) * 2021-05-26 2021-08-13 深圳市人民医院 醋酸巴多昔芬在治疗急性髓系白血病药物中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
TW383306B (en) * 1992-12-22 2000-03-01 Lilly Co Eli New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol
TW303299B (pt) * 1993-07-22 1997-04-21 Lilly Co Eli
ES2162198T3 (es) * 1996-04-19 2001-12-16 American Home Prod Agentes estrogenos.
US5998402A (en) * 1996-04-19 1999-12-07 American Home Products Corporation 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
US6583170B1 (en) * 1998-05-15 2003-06-24 Wyeth 2-Phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol and estrogen formulations
US6479535B1 (en) * 1998-05-15 2002-11-12 Wyeth 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
AR029538A1 (es) * 2000-07-06 2003-07-02 Wyeth Corp Composiciones farmaceuticas de agentes estrogenicos
CA2414111A1 (en) * 2000-07-06 2002-01-17 Wyeth Use of substituted indole compounds for increasing nitric oxide synthase activity
AU2001271784A1 (en) * 2000-07-06 2002-01-21 Wyeth Therapy for prosthesis-related bone degeneration
EP1192945A3 (en) * 2000-09-21 2004-03-03 Pfizer Products Inc. Use of an estrogen agonist/antagonist for treating osteoarthritis

Also Published As

Publication number Publication date
NO20044954L (no) 2004-12-16
CN1658868A (zh) 2005-08-24
RU2355397C2 (ru) 2009-05-20
ECSP045492A (es) 2005-03-10
CR7585A (es) 2008-10-03
CA2489098A1 (en) 2003-12-24
UA85374C2 (en) 2009-01-26
EP1531807A1 (en) 2005-05-25
MXPA04011634A (es) 2005-07-05
KR20050010886A (ko) 2005-01-28
NI200400065A (es) 2005-08-09
JP2005531613A (ja) 2005-10-20
EP1531807A4 (en) 2007-10-31
WO2003105834A1 (en) 2003-12-24
RU2004136316A (ru) 2005-05-10
US20040063692A1 (en) 2004-04-01
NZ537051A (en) 2007-11-30
ZA200409991B (en) 2007-09-26
SG162615A1 (en) 2010-07-29
IL165210A0 (en) 2005-12-18
AU2003248707A1 (en) 2003-12-31

Similar Documents

Publication Publication Date Title
BR0311774A (pt) regimes de tratamento com bazedoxifeno
PT1601694E (pt) Utilizações de agonistas e antagonistas de il-23; reagentes relacionados
TR200300322T2 (tr) Kemokin alıcısını bağlayan heterosiklik bileşikler
DE69929235D1 (de) Spiro-indole als y5-rezeptor antagonisten
NO20051042L (no) Pyrimidylsulfonamidderivater som kemokinreseptormodulatorer
DE10393089D2 (de) Vorrichtung zum Zuführen von Fluiden
NL1024261A1 (nl) Preparaten, die een indolinonverbinding bevatten.
ES1052161Y (es) Dispositivo homogeneizador batidor perfeccionado.
NO20034130D0 (no) Benzimidazolderivater som modulerer kjemokinreseptor
DE602005017378D1 (de) Vorrichtung zum zusammenhalten von flexiblen leitern
FR2886140B1 (fr) Composition pour la teinture des fibes keratiniques comprenant un derive de diamino-n,n-dihydro-pyrazolone et un derive de l'indole ou de l'indoline
EA200700949A1 (ru) Фармацевтические композиции, основанные на антагонистах nk2, для применения в педиатрической практике
ES1050942Y (es) Dispositivo de union autocentrante.
ITMI20032169A1 (it) Motore endotermico, specialmente per motociclette.
ITRM20020141U1 (it) Pedale per comandi elettrici, primari ed ausiliari.
BRPI0407690A (pt) composto, e, métodos para tratar endometriose e para tratar leiomioma uterino
ES1052452Y (es) Dispositivo para duplicado de emergencias dentales individualizadas.
NO20055493D0 (no) 8??-vinyl-11??-(w-substituerte)alkyl-ostra-1,3,5(10)-triener
NO20011382D0 (no) Oppsjekkbar anordning, særlig for bruk som luftveisÕpner for hest
ITTO20020264A1 (it) Dispositivo acquastop perfezionato.
ES1053445Y (es) Dispositivo antigoteo para botellas.
ITPV20020004A1 (it) Dispositivo per miscelare o amalgamare vernici, pitture o simili.
ES1050967U (es) Bloque ceramico perfeccionado.
ITRI20030009A1 (it) Dispositivo portatile per dialisi extracorporea.
ITPN20020037U1 (it) Bruciatore perfezionato per fuochi aperti.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. A61K 31/55; A61P 19/08, 19/10, 25/28, 3/06, 5/30, 9/00

Ipc: A61K 31/55 (2011.01), A61P 19/08 (2011.01), A61P 1

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 8A. ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE A 8A ANUIDADE.